drugset / Trial / NCT05800249
PE0116 Injection in Treatment of Patients With Advanced Solid Tumours
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I Clinical Trial to Evaluate the Tolerability, Safety, Pharmacokinetics and Preliminary Antitumor Activity of PE0116 Injection in Treatment of Patients with Advanced Solid Tumor.
Timeline
- Start
- 2021-03-08
- Primary completion
- 2023-06-02
- Completion
- 2023-06-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PE0116 | Monoclonal antibody | 0.03 mg/kg | — |
| Subject | PE0116 | Monoclonal antibody | 0.1 mg/kg | — |
| Subject | PE0116 | Monoclonal antibody | 0.3 mg/kg | — |
| Subject | PE0116 | Monoclonal antibody | 1 mg/kg | — |
| Subject | PE0116 | Monoclonal antibody | 2 mg/kg | — |
| Subject | PE0116 | Monoclonal antibody | 3 mg/kg | — |
| Subject | PE0116 | Monoclonal antibody | 5 mg/kg | — |
| Subject | PE0116 | Monoclonal antibody | 6 mg/kg | — |
| Subject | PE0116 | Monoclonal antibody | 10 mg/kg | — |